Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?

References

• YuKHSeeLCKuoCFChouIJChouMJPrevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in TaiwanArthritis Care Res (Hoboken)20136524425022899470
   PubMed Web of Science ®Google Scholar
• LaiCHLaiMSLaiKLChenHHChiuYMNationwide population-based epidemiologic study of rheumatoid arthritis in TaiwanClin Exp Rheumatol20123035836322513120
   PubMed Web of Science ®Google Scholar
• KlareskogLvan der HeijdeDde JagerJPTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet200436367568115001324
   PubMed Web of Science ®Google Scholar
• WeinblattMEKeystoneECFurstDEAdalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialArthritis Rheum200348354512528101
   PubMed Web of Science ®Google Scholar
• LipskyPEvan der HeijdeDMSt ClairEWInfliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupN Engl J Med20003431594160211096166
   PubMed Web of Science ®Google Scholar
• FurstDEBreedveldFCKaldenJRUpdated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)Ann Rheum Dis200362Suppl 2ii2ii914532138
   PubMed Web of Science ®Google Scholar
• WeinblattMEMethotrexate in rheumatoid arthritis: a quarter century of developmentTrans Am Clin Climatol Assoc2013124162523874006
   PubMedGoogle Scholar
• OrmeMEMacgilchristKSMitchellSSpurdenDBirdASystematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70Biologics2012642946423269860
   PubMedGoogle Scholar
• KamedaHKanbeKSatoEContinuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR studyJ Rheumatol2011381585159221572151
   PubMed Web of Science ®Google Scholar
• SolimanMMAshcroftDMWatsonKDLuntMSymmonsDPHyrichKLImpact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterAnn Rheum Dis20117058358921330639
   PubMed Web of Science ®Google Scholar
• LedinghamJDeightonCUpdate on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)Rheumatology (Oxford)20054415716315637039
   PubMed Web of Science ®Google Scholar
• WolfeFThe epidemiology of drug treatment failure in rheumatoid arthritisBailliere’s Clin Rheumatol199596196328591645
   PubMed Web of Science ®Google Scholar
• Martinez-SantanaVGonzalez-SarmientoECalleja-HernandezMSanchez-SanchezTComparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritisPatient Prefer Adherence2013771972724023512
   PubMed Web of Science ®Google Scholar
• MarchesoniAZaccaraEGorlaRTNF-α antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practiceAnn N Y Acad Sci2009117383784619758236
   PubMed Web of Science ®Google Scholar
• IannoneFGremeseEAtzeniFLongterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictorsJ Rheumatol2012391179118422467933
   PubMed Web of Science ®Google Scholar
• StrangfeldAHierseFKekowJComparative effectiveness of tumour necrosis factor α inhibitors in combination with either methotrexate or leflunomideAnn Rheum Dis2009681856186219126559
   PubMed Web of Science ®Google Scholar
• HetlandMLChristensenIJTarpUDirect comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registryArthritis Rheum201062223220039405
   PubMed Web of Science ®Google Scholar
• Gomez-ReinoJJCarmonaLSwitching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year periodArthritis Res Ther20068R2916507128
   PubMed Web of Science ®Google Scholar
• BorahBJHuangXZarotskyVGlobeDTrends in RA patients’ adherence to subcutaneous anti-TNF therapies and costsCurr Med Res Opin2009251365137719425902
   PubMed Web of Science ®Google Scholar
• TubachFSalmonDRavaudPGlobeDRisk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registryArthritis Rheum2009601884189419565495
   PubMed Web of Science ®Google Scholar
• DixonWGHyrichKLWatsonKDDrug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Ann Rheum Dis20106952252819854715
   PubMed Web of Science ®Google Scholar
• NavarraSVTangBLuLRisk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in AsiaInt J Rheum Dis20141729129824131578
   PubMed Web of Science ®Google Scholar
• MorelandLWInhibitors of tumor necrosis factor for rheumatoid arthritisJ Rheumatol Suppl19995771510328137
   PubMedGoogle Scholar
• ScallonBCaiASolowskiNBinding and functional comparisons of two types of tumor necrosis factor antagonistsJ Pharmacol Exp Ther200230141842611961039
   PubMed Web of Science ®Google Scholar
• MitomaHHoriuchiTTsukamotoHMechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor α-expressing cells: comparison among infliximab, etanercept, and adalimumabArthritis Rheum2008581248125718438840
   PubMed Web of Science ®Google Scholar
• SchellekensHImmunogenicity of therapeutic proteins: clinical implications and future prospectsClin Ther20022417201740 discussion 171912501870
   PubMed Web of Science ®Google Scholar
• WolbinkGJAardenLADijkmansBADealing with immunogenicity of biologicals: assessment and clinical relevanceCurr Opin Rheumatol20092121121519399992
   PubMed Web of Science ®Google Scholar
• FleischmannRShealyDDeveloping a new generation of TNFα antagonists for the treatment of rheumatoid arthritisMol Interv2003331031814993463
   PubMedGoogle Scholar
• BarteldsGMKrieckaertCLNurmohamedMTDevelopment of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-upJAMA20113051460146821486979
   PubMed Web of Science ®Google Scholar
• KrieckaertCLJamnitskiANurmohamedMTKostensePJBoersMWolbinkGComparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicityArthritis Rheum2012643850385522933315
   PubMed Web of Science ®Google Scholar
• KrieckaertCLNurmohamedMTWolbinkGJMethotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent mannerAnn Rheum Dis2012711914191522586169
   PubMed Web of Science ®Google Scholar
• ArnettFCEdworthySMBlochDAThe American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritisArthritis Rheum1988313153243358796
   PubMed Web of Science ®Google Scholar
• DeyoRACherkinDCCiolMAAdapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJ Clin Epidemiol1992456136191607900
   PubMed Web of Science ®Google Scholar
• ChenDYChenYMTsaiWCSignificant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritisAnn Rheum Dis201574e1624442879
   PubMed Web of Science ®Google Scholar
• BurmesterGRKivitzAJKupperHEfficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trialAnn Rheum Dis2015741037104424550168
   PubMed Web of Science ®Google Scholar
• KristensenLEKapetanovicMCGulfeASoderlinMSaxneTGeborekPPredictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group RegisterRheumatology (Oxford)20084749549918316338
   PubMed Web of Science ®Google Scholar